The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial

• Published in: The pharmacogenomics journal 2023-11, Vol.23 (6), p.169-177
• Main Authors: Eadon, Michael T., Rosenman, Marc B., Zhang, Pengyue, Fulton, Cathy R., Callaghan, John T., Holmes, Ann M., Levy, Kenneth D., Gupta, Samir K., Haas, David M., Vuppalanchi, Raj, Benson, Eric A., Kreutz, Rolf P., Tillman, Emma M., Shugg, Tyler, Pierson, Rebecca C., Gufford, Brandon T., Pratt, Victoria M., Zang, Yong, Desta, Zeruesenay, Dexter, Paul R., Skaar, Todd C.
• Format: Article
• Language: English
• Subjects: 631/154/436/434; 631/208/212/1728; Adverse events; Aripiprazole; Biomedical and Life Sciences; Biomedicine; Clinical trials; Drug-Related Side Effects and Adverse Reactions - genetics; Gene Expression; Human Genetics; Humans; Indigent care; Morbidity; Mortality; Norepinephrine; Oncology; Pharmacogenomic Testing; Pharmacotherapy; Psychopharmacology; Serotonin; Terminology
• ISSN: 1470-269X; 1473-1150; 1473-1150
• DOI: 10.1038/s41397-023-00315-w

Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden. Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of this INGENIOUS trial (NCT02297126) analysis was to determine whether conducting and reporting pharmacogenetic panel testing impacts ADE frequency. The trial was a pragmatic, randomized controlled clinical trial, adapted as a propensity matched analysis in individuals ( N  = 2612) receiving a new prescription for one or more of 26 pharmacogenetic-actionable drugs across a community safety-net and academic health system. The intervention was a pharmacogenetic testing panel for 26 drugs with dosage and selection recommendations returned to the health record. The primary outcome was occurrence of ADEs within 1 year, according to modified Common Terminology Criteria for Adverse Events (CTCAE). In the propensity-matched analysis, 16.1% of individuals experienced any ADE within 1-year. Serious ADEs (CTCAE level ≥ 3) occurred in 3.2% of individuals. When combining all 26 drugs, no significant difference was observed between the pharmacogenetic testing and control arms for any ADE (Odds ratio 0.96, 95% CI: 0.78–1.18), serious ADEs (OR: 0.91, 95% CI: 0.58–1.40), or mortality (OR: 0.60, 95% CI: 0.28–1.21). However, sub-group analyses revealed a reduction in serious ADEs and death in individuals who underwent pharmacogenotyping for aripiprazole and serotonin or serotonin-norepinephrine reuptake inhibitors (OR 0.34, 95% CI: 0.12–0.85). In conclusion, no change in overall ADEs was observed after pharmacogenetic testing. However, limitations incurred during INGENIOUS likely affected the results. Future studies may consider preemptive, rather than reactive, pharmacogenetic panel testing.